Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.67 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15670501 | 1.00 | BTK (0.67) | BTKEGFRSRC | |
| SCHEMBL15670185 | 0.94 | BTK (0.66) | BTKEGFRSRC | |
| SCHEMBL15472784 | 0.94 | BTK (0.66) | BTKEGFRSRC | |
| SCHEMBL15669314 | 0.94 | BTK (0.66) | BTKEGFRSRC | |
| SCHEMBL15670221 | 0.94 | BTK (0.72) | BTKEGFRSRC | |
| Hydrochloric Acid SCHEMBL15756445 | 0.93 | BTK (0.65) | BTKEGFRSRC | |
| Hydrochloric Acid SCHEMBL15756442 | 0.93 | BTK (0.65) | BTKEGFRSRC | |
| SCHEMBL15669732 | 0.92 | BTK (0.71) | BTKEGFRSRC | |
| SCHEMBL18700112 | 0.90 | BTK (0.53) | BTKEGFRSRC | |
| SCHEMBL15670119 | 0.88 | BTK (0.67) | BTKEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105884747-B | Preparation method for preparing Bruton's Tyrosine Kinase (BTK) kinase inhibitor | 首药控股(北京)有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-10112922-B2 | Inhibitor of bruton's tyrosine kinase | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2018-10-30 | — | — | US | disclosed |
| US-20170144986-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-05-25 | — | — | US | disclosed |
| EP-3141546-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | Centaurus Biopharma Co., Ltd. (CN) | 2017-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144986-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | BTK 1/4885EGFR 618/4885SRC 6/4885 |
| US-10112922-B2 | Inhibitor of bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885EGFR 618/4885SRC 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.